SCHEMBL13627917

SCHEMBL13627917

Cc1ccc2c(c1)/C(=N/O)C(=O)N2Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.52
ALDH1A1 P00352 7/20 0.51
MAPT P10636 4/20 0.51
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
HSP90AA1 P07900 1/20 0.49
ALDH2 P05091 3/20 0.49
ALDH3A1 P30838 3/20 0.49
PKM P14618 2/20 0.48
LRRK2 Q5S007 1/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CHRM1 P11229 1/20 0.48
CES1 P23141 1/20 0.48
TP53 P04637 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627921 0.92 ACHE (0.58) ACHEALDH1A1MAPTLMNAPOLB
SCHEMBL13627922 0.91 ACHE (0.48) ACHEALDH1A1MAPTLMNAPOLB
SCHEMBL13627889 0.88 ACHE (0.54) ACHEALDH1A1MAPTLMNAPOLB
SCHEMBL13627919 0.87 ACHE (0.53) ACHEALDH1A1MAPTLMNAPOLB
SCHEMBL13627923 0.87 UBE2N (0.52) ACHEALDH1A1MAPTLMNAPOLB
SCHEMBL13627927 0.85 ALDH3A1 (0.68) ALDH1A1MAPTALDH2ALDH3A1PKM
SCHEMBL13627900 0.84 ALDH1A1 (0.69) ACHEALDH1A1MAPTALDH2ALDH3A1
SCHEMBL13627936 0.84 TRPA1 (0.62) ALDH1A1MAPTALDH2ALDH3A1PKM
SCHEMBL13627933 0.84 TP53 (0.53) ALDH1A1MAPTLMNAPOLBALDH2
SCHEMBL13627880 0.84 ALDH1A1 (0.70) ACHEALDH1A1MAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ACHE 4079/4885ALDH1A1 4310/4885MAPT 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.